Interviews on biotechnology

immutep checkpoint inhibitor lag 3 cancer

Interview 29 Nov 2022

LAG-3: The next big checkpoint inhibitor target

Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of […]

November 29, 2022 - 7 minutesmins - By Jonathan Smith

Miquel Vila Perelló gene therapy SpliceBio

Interview 28 Nov 2022

Breaking barriers to gene therapies for childhood rare diseases

The majority of known rare genetic diseases affect children, and gene therapies could help them live normal lives. Miquel Vila-Perelló, CEO and co-founder of the Spanish biotech SpliceBio, outlines how its technology could widen the range of genetic diseases treatable with gene therapies. Last week, World Children’s Day was celebrated as a means to improve […]

November 28, 2022 - 5 minutesmins - By Jonathan Smith

Ulrich dauer vivoryon alzheimers disease

Interview 23 Nov 2022

What recent mixed clinical results can teach about Alzheimer’s disease

2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a treatment to slow the progression of Alzheimer’s disease has endured decades of disappointments. The most common treatment strategy — clearing up harmful deposits, or “plaques,” […]

November 23, 2022 - 7 minutesmins - By Jonathan Smith

Interview 18 Nov 2022

How cardioids can usher in the next generation of drug discovery

The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Despite this, the cardiovascular therapeutics market has lagged behind the […]

November 18, 2022 - 6 minutesmins - By Omnia Ibrahim

Interview 14 Nov 2022

MaaT Pharma: leading the charge in microbiome therapeutics

The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech MaaT Pharma outlines the firm’s efforts to blaze a trail in clinical testing and manufacturing in the new field. The microbiome world recently made a regulatory step forward as Australia greenlit a stool transplant developed […]

November 14, 2022 - 5 minutesmins - By Jonathan Smith

Interview 14 Nov 2022

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […]

November 14, 2022 - 9 minutesmins - By Jim Cornall

Interview 7 Nov 2022

AI could tackle pharmaceutical manufacturing bottlenecks

Artificial intelligence (AI) is making waves in the world of drug discovery. Rajiv Anand, founder and CEO of the firm Quartic.ai, explains how the tool could also make pharmaceutical manufacturing more efficient. The use of AI in drug discovery is attracting big investor interest; around $1.4 billion so far this year has gone to startups […]

November 7, 2022 - 6 minutesmins - By Jonathan Smith

longevity treatment bioAge Kristen Fortney

Interview 31 Oct 2022

AI and biobanks could open the way to longevity treatments

The development of longevity treatments is hampered by a lack of biomarkers and validated drug targets. BioAge’s co-founder and CEO, Kristen Fortney, explains how the firm is enlisting machine learning (ML), artificial intelligence (AI) and biobanks to fill in the gaps. The quest for human longevity treatments is attracting big cash in the biotech industry. […]

October 31, 2022 - 7 minutesmins - By Jonathan Smith

Interview 28 Oct 2022

Migraines: a new vaccine frontier beyond infectious diseases

By bringing the efficiency and affordability of vaccines to chronic diseases such as migraines, U.S. company Vaxxinity aims to open a new frontier for vaccines in an effort to reach all patient populations, regardless of location or income. Migraine causes severe headaches that are characterized by throbbing pain and associated symptoms such as sensitivity to […]

October 28, 2022 - 7 minutesmins - By Omnia Ibrahim

Caszyme crispr climate change Anastasiia Slynko

Interview 17 Oct 2022

CRISPR gene editing: a key tool for counteracting climate change

Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing technology could fight climate change by boosting agriculture and biodiversity. The invention of CRISPR-Cas gene editing technology in the last decade sparked a revolution in biology, providing researchers a way to make selective and precise changes to an organism’s genetic […]

October 17, 2022 - 6 minutesmins - By Jonathan Smith

Mike Nally Generate Biomedicines ai drug discovery

Interview 12 Oct 2022

Boosting pharma’s falling productivity with AI in drug discovery

The pharmaceutical industry is struggling with mounting costs of drug development. Generate Biomedicines’ CEO, Michael Nally, outlines the firm’s mission to tackle the trend by making drug discovery scalable. Over the decades, the pharma and biopharma industry has suffered a growing stagnation in productivity. According to a report from University College London in 2018, for […]

October 12, 2022 - 5 minutesmins - By Jonathan Smith

Interview 28 Sep 2022

How the alternative protein space aims to address food waste

Food waste impacts the whole of society, including the field of alternative protein. Nick Cooney, managing partner of Lever VC, explains how companies and investors in the space aim to tackle the global problem. This week, the UN and its food security-focused arm, the Food and Agriculture Organization, celebrate the International Day of Awareness of […]

September 28, 2022 - 7 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us